Related Experiment Video
Updated: Jun 4, 2026
Assays for the Specific Growth Rate and Cell-binding Ability of Rotavirus
Published on: January 28, 2019
Evaluation of rotavirus vaccines in small animal models
1Division of Molecular Virology, Baylor College of Medicine, Houston, TX.
Insights
Developing nonreplicating rotavirus (RV) vaccines requires overcoming challenges in inducing mucosal immunity. Enhancing immunogenicity through adjuvants, delivery systems, and alternative immunization routes is crucial for effective RV protection.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- Rotavirus (RV) infections cause significant morbidity and mortality, particularly in children, necessitating vaccine development.
- While natural RV infection confers protection against severe disease, the underlying immunologic mechanisms, particularly intestinal antibody responses, are not fully understood.
- Live attenuated oral RV vaccines like Rotashield™ have shown promise but face challenges including potential reassortment with wild-type viruses and interference.
Purpose of the Study:
- To explore the development and testing of nonreplicating rotavirus (RV) vaccines.
- To address the challenges associated with inducing protective immune responses using nonreplicating immunogens.
- To investigate strategies for enhancing the immunogenicity and efficacy of nonreplicating RV vaccines.
Main Methods:
- Focus on the development and testing of nonreplicating RV vaccine candidates.
- Investigate the ability of nonreplicating immunogens to induce protective immune responses.
- Explore the use of adjuvants, novel delivery systems, and alternative immunization routes to enhance immunogenicity.
Main Results:
- Nonreplicating RV vaccines present unique challenges in inducing mucosal immunity and protection.
- Higher doses of nonreplicating immunogens may be required due to the absence of viral replication.
- Development of new adjuvants, delivery systems, and immunization strategies is needed to boost efficacy.
Conclusions:
- Nonreplicating RV vaccines require innovative approaches to achieve protective immunity, especially in young children.
- Enhancing immunogenicity and stability of oral nonreplicating immunogens is critical for successful vaccine design.
- Further research into adjuvants, delivery systems, and immunization routes is essential for advancing nonreplicating RV vaccine development.
Abstract:
The high morbidity and mortality of rotavirus (RV) infections has spurred the development of RV vaccines (1-13). Although children naturally infected with RV commonly undergo multiple infections, primary infections in children generally induce disease, and children are normally protected against severe disease during subsequent infections (1,2,6-8,14). For RV, the immunologic mechanisms responsible for protection are poorly understood, but antibody (Ab) in the intestine appears to be the primary mechanism of protection (2,15,16). Because RV is a localized enteric infection, and induction of intestinal mucosal immune responses was expected to be required for protection, live orally administered vaccines were pursued first. Vaccine development of the live attenuated vaccines proceeded to clinical trials in humans without prior animal testing. In August 1998, Rotashield™, a three dose, live attenuated tetravalent (TV), rhesus rotavirus (RRV) vaccine produced by Wyeth Lederle Vaccines and Pediatrics (West Henrietta, NY), was licensed. This vaccine shows promise, eliciting ∼80% protection against severe disease (6,7,12,17-19). The recent detection or emergence of new RV serotypes in humans suggests that incorporation of additional P-and G-serotypes into this vaccine may be necessary in the future (20-22). Additional concerns with the use of live attenuated vaccines include interference of vaccine replication by other enteric pathogens (common in children from the underdeveloped world); neutralization by maternal Ab; limited replication competence of animal strains, because of the host range restriction observed with RVs; and safety, because of the possibility of producing new virulent virus, emerging by reassortment of circulating wild-type (WT) virus with the vaccine virus.Development and testing of nonreplicating RV vaccines have also been pursued, and will be the focus of this chapter. The use of nonreplicating immunogens presents additional challenges beyond that of developing RV vaccines effective in young children against potential infection by multiple serotypes of RV. The nonreplicating immunogen must be able to induce protective immune responses against the target virus. Traditionally, nonreplicating vaccines have been thought to be poor inducers of mucosal immune responses and protection of the mucosa. Without amplification of the vaccine virus by replication, a high dose of nonreplicating immunogen may be required. To enhance the immune response to nonreplicating immunogens, development and testing of new adjuvants and/or delivery systems, and alternative routes of immunization to boost immunogenicity and protective efficacy, are needed. If administered orally, the nonreplicating immunogens must be stable in the digestive environments of the stomach and intestine.
